Record revenues and profits were achieved, driven by new product launches, expanded manufacturing, and strong market share in key generics. The company maintains a robust pipeline, low debt, and is evaluating M&A and Nasdaq uplisting while continuing internal growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.